Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response
The DOI matches its Crossref record.
Abstract
No AccessJournal of UrologyUrological Survey: Abstracts: Renal Tumors, Retroperitoneum, Ureter, and Urinary Diversion and Reconstruction1 Aug 1999Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response S.A. Rosenberg, J.C. Yang, D.E. White, and S.M. Steinberg S.A. RosenbergS.A. Rosenberg More articles by this author , J.C. YangJ.C. Yang More articles by this author , D.E. WhiteD.E. White More articles by this author , and S.M. SteinbergS.M. Steinberg More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68669-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response." The Journal of Urology, 162(2), p. 637 Surgery Branch, and Department of Biostatistics and Data Management Section, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 162Issue 2August 1999Page: 637 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information S.A. Rosenberg More articles by this author J.C. Yang More articles by this author D.E. White More articles by this author S.M. Steinberg More articles by this author Expand All Advertisement PDF downloadLoading ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationAdoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Self-citationIL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Self-citationRoyal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Self-citationToward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Self-citationDowney, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Self-citationIpilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 557
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Self-citationCTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477
Self-citationExploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
“200 TBI 25 8 (32) (3, 3–6, 6, 9, 14) 5 (20) (95+, 91+, 87+, 84+, 81+) 13 (52) 1200 TBI 25 8 (32) (2, 3, 5, 6, 6, 7, 13, 21) 10 (40) (75+, 73+, 71+, 71+, 66+, 65+, 65+, 65+, 64+, 19) 18 (72)”
Self-citationKlapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 434
Self-citationCurrent clinical trials testing the combination of immunotherapy with radiotherapy
Kang, J., Demaria, S., & Formenti, S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0156-7 · Cited by 371
Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I. J., Larsen, S., Gehl, J., & von der Maase, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602702 · Cited by 329
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304
Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286
Self-citationLu, Y.-C., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 279
Self-citationZhang, Y., Li, N., Suh, H., & Irvine, D. J. (2018) · Nature Communications · doi:10.1038/s41467-017-02251-3 · Cited by 248
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 244
Self-citationTreatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239
“org Clin Cancer Res 2008;14(17) September1, 2008 5611”
BackgroundInfluentialSelf-citationTumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 237
“6% complete response 19% Expected IL-2 related side effects [46]”
Radiation-induced effects and the immune system in cancer
Kaur, P., & Asea, A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00191 · Cited by 229
“The immunological clinical success story in metastatic melanoma is high-dose IL-2, which causes durable regression of significant disease in a subpopulation of patients (Rosenberg et al., 1998).”
BackgroundSun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11782-w · Cited by 211
Sarcomatoid renal cell carcinoma: biology, natural history and management
Blum, K. A., Gupta, S., Tickoo, S. K., Chan, T. A., Russo, P., Motzer, R. J., Karam, J. A., & Hakimi, A. A. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00382-9 · Cited by 203
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Immunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81
Self-citation
Metadata
- Authors
- Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M.
- Venue
- Journal of Urology
- Published
- 1999-08
- Volume
- 162
- Issue
- 2
- Pages
- 637-637
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2055087053
- Cited by
- 116
- References
- 0
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.